{"id":"https://openalex.org/W1990312367","doi":"https://doi.org/10.1038/sj.bjp.0707160","title":"F15063, a compound with D2/D3antagonist, 5\u2010HT1Aagonist and D4partial agonist properties: (III) Activity in models of cognition and negative symptoms","display_name":"F15063, a compound with D2/D3antagonist, 5\u2010HT1Aagonist and D4partial agonist properties: (III) Activity in models of cognition and negative symptoms","alternate_titles":[],"publication_year":2007,"publication_date":"2007-05-01","ids":{"openalex":"https://openalex.org/W1990312367","doi":"https://doi.org/10.1038/sj.bjp.0707160","mag":"1990312367","pmid":"https://pubmed.ncbi.nlm.nih.gov/17375085","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2013949"},"language":"en","primary_location":{"id":"doi:10.1038/sj.bjp.0707160","doi":"https://doi.org/10.1038/sj.bjp.0707160","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0707160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0707160","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1990312367"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0707160","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000797879","display_name":"Ronan Depoort\u00e8re","orcid":"https://orcid.org/0000-0003-0970-420X","observed_orcids":["https://orcid.org/0000-0003-0970-420X"]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"R Depoort\u00e8re","raw_affiliation_strings":["Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France. ronan.depoortere@pierre-fabre.com","Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France. ronan.depoortere@pierre-fabre.com","institution_ids":[]},{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062308579","display_name":"Agn\u00e8s L. Auclair","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A L Auclair","raw_affiliation_strings":["Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080830822","display_name":"Laurent Bardin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L Bardin","raw_affiliation_strings":["Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083537506","display_name":"Liesbeth A. Bruins Slot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"L Bruins Slot","raw_affiliation_strings":["Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083060102","display_name":"Mark S. Kleven","orcid":"https://orcid.org/0000-0001-5413-4475","observed_orcids":["https://orcid.org/0000-0001-5413-4475"]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M S Kleven","raw_affiliation_strings":["Current address: Yaupon Therapeutics Inc, 259 North Radnor, Chester Road, Suite 220, Radnor, PA 19087, USA","Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Current address: Yaupon Therapeutics Inc, 259 North Radnor, Chester Road, Suite 220, Radnor, PA 19087, USA","institution_ids":[]},{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109195052","display_name":"Fran\u00e7is C. Colpaert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F Colpaert","raw_affiliation_strings":["Research Management, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research Management, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046760267","display_name":"Bernard Vacher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"B Vacher","raw_affiliation_strings":["Medical Chemistry Division 1, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Chemistry Division 1, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045801598","display_name":"Adrian Newman\u2010Tancredi","orcid":"https://orcid.org/0000-0002-2923-5714","observed_orcids":["https://orcid.org/0000-0002-2923-5714"]},"institutions":[{"id":"https://openalex.org/I4210143394","display_name":"Pierre Fabre (France)","ror":"https://ror.org/04hdhz511","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210143394"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A Newman\u2010Tancredi","raw_affiliation_strings":["Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France","institution_ids":["https://openalex.org/I4210143394"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5000797879"],"corresponding_institution_ids":["https://openalex.org/I4210143394"],"apc_list":{"value":4780,"currency":"USD","value_usd":4780},"apc_paid":null,"fwci":5.4529,"has_fulltext":true,"cited_by_count":55,"citation_normalized_percentile":{"value":0.95944705,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"151","issue":"2","first_page":"266","last_page":"277"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9193999767303467,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9193999767303467,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0729999989271164,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/5-ht1a-receptor-agonist","display_name":"5-HT1A receptor agonist","score":0.9950000047683716},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7720000147819519},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.9879999756813049},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.9909999966621399},{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.7450000047683716},{"id":"https://openalex.org/keywords/scopolamine","display_name":"scopolamine","score":0.7950000166893005},{"id":"https://openalex.org/keywords/reversal-learning","display_name":"reversal learning","score":0.6930000185966492},{"id":"https://openalex.org/keywords/social-recognition-memory","display_name":"social recognition memory","score":0.7250000238418579},{"id":"https://openalex.org/keywords/prepulse-inhibition","display_name":"prepulse inhibition","score":0.9449999928474426},{"id":"https://openalex.org/keywords/sensorimotor-gating","display_name":"sensorimotor gating","score":0.9169999957084656},{"id":"https://openalex.org/keywords/glutamatergic-dysfunction","display_name":"glutamatergic dysfunction","score":0.699999988079071},{"id":"https://openalex.org/keywords/cholinergic-dysfunction","display_name":"cholinergic dysfunction","score":0.8920000195503235}],"concepts":[{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.7161566019058228},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6795006990432739},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.6616131663322449},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.6513711214065552},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.603748619556427},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.5734108686447144},{"id":"https://openalex.org/C22885893","wikidata":"https://www.wikidata.org/wiki/Q4862743","display_name":"Cholinergic","level":2,"score":0.5647894144058228},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4982450008392334},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.46744000911712646},{"id":"https://openalex.org/C2778539182","wikidata":"https://www.wikidata.org/wiki/Q4693408","display_name":"Agonist-antagonist","level":4,"score":0.46000224351882935},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.4045596122741699},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.38052019476890564},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31798049807548523},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.3073817789554596},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2681383490562439},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.21522945165634155},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.08455502986907959}],"mesh":[{"descriptor_ui":"D000647","descriptor_name":"Amnesia","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D000647","descriptor_name":"Amnesia","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001522","descriptor_name":"Behavior, Animal","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001596","descriptor_name":"Benzylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D003517","descriptor_name":"Cyclopentanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012018","descriptor_name":"Reflex","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013216","descriptor_name":"Reflex, Startle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017366","descriptor_name":"Serotonin Receptor Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018492","descriptor_name":"Dopamine Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D023421","descriptor_name":"Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050637","descriptor_name":"Receptors, Dopamine D3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D050638","descriptor_name":"Receptors, Dopamine D4","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058825","descriptor_name":"Serotonin 5-HT1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058829","descriptor_name":"Serotonin 5-HT1 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065127","descriptor_name":"Dopamine D2 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/sj.bjp.0707160","doi":"https://doi.org/10.1038/sj.bjp.0707160","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0707160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0707160","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2013949","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2013949/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Pharmacol","raw_type":"Text"},{"id":"pmid:17375085","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17375085","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1038/sj.bjp.0707160","doi":"https://doi.org/10.1038/sj.bjp.0707160","is_oa":true,"landing_page_url":"https://doi.org/10.1038/sj.bjp.0707160","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1038/sj.bjp.0707160","source":{"id":"https://openalex.org/S55107261","display_name":"British Journal of Pharmacology","issn_l":"0007-1188","issn":["0007-1188","1476-5381"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1990312367.pdf","grobid_xml":"https://content.openalex.org/works/W1990312367.grobid-xml"},"referenced_works_count":61,"referenced_works":["https://openalex.org/W1927413935","https://openalex.org/W1963709344","https://openalex.org/W1964176367","https://openalex.org/W1965196644","https://openalex.org/W1965657753","https://openalex.org/W1970167327","https://openalex.org/W1974793630","https://openalex.org/W1976539696","https://openalex.org/W1983805722","https://openalex.org/W1985150585","https://openalex.org/W1993614905","https://openalex.org/W1995108153","https://openalex.org/W2000375438","https://openalex.org/W2000445907","https://openalex.org/W2002179561","https://openalex.org/W2002495110","https://openalex.org/W2003935114","https://openalex.org/W2005756201","https://openalex.org/W2006729014","https://openalex.org/W2011023694","https://openalex.org/W2014801474","https://openalex.org/W2016943172","https://openalex.org/W2033469254","https://openalex.org/W2035815094","https://openalex.org/W2038587452","https://openalex.org/W2039066505","https://openalex.org/W2043773675","https://openalex.org/W2044398497","https://openalex.org/W2046768361","https://openalex.org/W2052578687","https://openalex.org/W2057377147","https://openalex.org/W2060884332","https://openalex.org/W2062621766","https://openalex.org/W2067136937","https://openalex.org/W2068337150","https://openalex.org/W2069849124","https://openalex.org/W2071647676","https://openalex.org/W2072679875","https://openalex.org/W2074944650","https://openalex.org/W2083445063","https://openalex.org/W2085861484","https://openalex.org/W2086049275","https://openalex.org/W2091240406","https://openalex.org/W2093248761","https://openalex.org/W2112440412","https://openalex.org/W2116043221","https://openalex.org/W2123633329","https://openalex.org/W2130322124","https://openalex.org/W2132939399","https://openalex.org/W2146709629","https://openalex.org/W2158137297","https://openalex.org/W2161155466","https://openalex.org/W2165378197","https://openalex.org/W2168280973","https://openalex.org/W2212944056","https://openalex.org/W2261115999","https://openalex.org/W2313653727","https://openalex.org/W2401206973","https://openalex.org/W2406143870","https://openalex.org/W2415246766","https://openalex.org/W4251169171"],"related_works":["https://openalex.org/W2074944650","https://openalex.org/W2002495110","https://openalex.org/W2007760893","https://openalex.org/W1984815383","https://openalex.org/W2068337150","https://openalex.org/W3010499360","https://openalex.org/W2275861028","https://openalex.org/W2089412776","https://openalex.org/W2063823937","https://openalex.org/W1975351746"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,212],"PURPOSE:":[2],"The":[3,214],"D(2)/D(3)":[4],"receptor":[5,8,15,221],"antagonist,":[6],"D(4)":[7,176,185,218],"partial":[9,177],"agonist,":[10],"and":[11,24,219,236],"high":[12],"efficacy":[13,55],"5-HT(1A)":[14,89,220],"agonist":[16],"F15063":[17,37,91,123,128,147,189,224],"was":[18,67,181],"shown":[19],"to":[20,113,191],"be":[21],"highly":[22],"efficacious":[23],"potent":[25],"in":[26,50,69,137,155,168,204,231],"rodent":[27],"models":[28,52,70,232],"of":[29,34,54,60,71,163,201,208,216,223,229,233,239],"activity":[30,230],"against":[31,56,144],"positive":[32],"symptoms":[33,238],"schizophrenia.":[35,61,240],"However":[36],"induced":[38,74],"neither":[39],"catalepsy":[40],"nor":[41],"the":[42,78,184],"'serotonin":[43],"syndrome'.":[44],"Here,":[45],"we":[46],"evaluated":[47],"its":[48,111,175],"profile":[49,228],"rat":[51,158],"predictive":[53],"negative":[57,115,237],"symptoms/cognitive":[58],"deficits":[59,73,235],"EXPERIMENTAL":[62],"APPROACH:":[63],"F15063,":[64],"given":[65],"i.p.,":[66],"assessed":[68],"behavioural":[72],"by":[75,108,126,183],"interference":[76],"with":[77,174],"NMDA/glutamatergic":[79],"(phencyclidine:":[80],"PCP)":[81],"or":[82],"cholinergic":[83],"(scopolamine)":[84],"systems.":[85],"KEY":[86],"RESULTS:":[87],"Through":[88],"activation,":[90],"partially":[92],"alleviated":[93],"(MED:":[94],"0.04":[95],"mg":[96,121,130,149,193],"kg(-1))":[97,131,150],"PCP-induced":[98],"social":[99,159],"interaction":[100,125],"deficit":[101],"between":[102],"two":[103],"adult":[104],"rats,":[105,205],"without":[106],"effect":[107],"itself,":[109],"underlining":[110],"potential":[112,143],"combat":[114],"symptoms.":[116],"At":[117],"doses":[118],"above":[119],"0.16":[120],"kg(-1),":[122],"reduced":[124],"itself.":[127],"(0.16":[129],"selectively":[132],"re-established":[133],"PCP-impaired":[134],"'cognitive":[135],"flexibility'":[136],"a":[138,156,164,206,226],"reversal":[139],"learning":[140],"task,":[141],"suggesting":[142],"adaptability":[145],"deficits.":[146],"(0.04-0.63":[148],"also":[151],"reversed":[152],"scopolamine-induced":[153],"amnesia":[154],"juvenile-adult":[157],"recognition":[160],"test,":[161],"indicative":[162],"pro-cholinergic":[165],"influence.":[166],"Activity":[167],"this":[169],"latter":[170],"test":[171],"is":[172],"consistent":[173],"agonism,":[178],"as":[179],"it":[180],"blocked":[182],"antagonist":[186],"L745,870.":[187],"Finally,":[188],"up":[190],"40":[192],"kg(-1)":[194],"did":[195],"not":[196],"disrupt":[197],"basal":[198],"prepulse":[199],"inhibition":[200],"startle":[202],"reflex":[203],"marker":[207],"sensorimotor":[209],"gating.":[210],"CONCLUSIONS":[211],"IMPLICATIONS:":[213],"balance":[215],"D(2)/D(3),":[217],"interactions":[222],"yields":[225],"promising":[227],"cognitive":[234]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1990312367","counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
